Welcome to our dedicated page for NYSE news (Ticker: NYSE), a resource for investors and traders seeking the latest updates and insights on NYSE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NYSE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NYSE's position in the market.
Actinium Pharmaceuticals (NYSE: ATNM) presented preclinical AACR 2026 data showing ATNM-400, an Ac-225 radioconjugate, with pan-tumor activity in prostate, EGFR-mutant lung, and HER2+ breast cancer models.
Data show efficacy in low/negative PSMA prostate models, superior activity versus several approved ADCs and targeted agents, durable control post-treatment in breast models, and no in vivo toxicities at therapeutic doses.
Actinium (NYSE:ATNM) presented AACR 2026 data showing that Actimab-A (lintuzumab-Ac225) drives mutation-agnostic anti-leukemic activity via transcriptional reprogramming, shifting AML cells from proliferation toward differentiation and apoptosis. Combinations with revumenib, gilteritinib, and azacitidine enhanced in vivo killing across models and primary patient samples, independent of FLT3, NPM1, KMT2A, IDH1/2, or TP53 status. Prior clinical work in >150 AML patients showed a manageable safety profile and supports Actimab-A as a universal combination backbone across AML treatment settings.
Lockheed Martin (NYSE: LMT) received a $4.7 billion undefinitized contract action (UCA) on April 10, 2026 to accelerate production of PAC-3 Missile Segment Enhancement (MSE) interceptors.
The award builds on a Jan. 6 framework agreement under the Department of War Acquisition Transformation Strategy and follows company investments of >$7 billion, including ~$2 billion for munitions acceleration, plus new production facilities and workforce expansion.
Actinium Pharmaceuticals (NYSE: ATNM) announced two AACR 2026 abstracts to be presented April 21, 2026, highlighting new preclinical data for ATNM-400 and a differentiated mechanism for Actimab-A. ATNM-400 shows pan-tumor Ac-225 radioconjugate activity; Actimab-A shows mutation-agnostic transcriptional reprogramming that may enhance AML therapy response. Posters: ATNM-400 #5824 and Actimab-A #5827 in session Radiopharmaceutical Platforms for Theranostic Precision Oncology, April 21, 2:00–5:00 PM PT, Poster Section 16.
Lockheed Martin (NYSE: LMT) and the Department of War announced a framework agreement to accelerate production of Precision Strike Missiles (PrSM), building on a prior $4.94 billion Army contract and aiming to quadruple PrSM production capacity. The deal includes the ability to negotiate a multi‑year contract up to seven years, contingent on future congressional authorization. Lockheed cites >115,000 sq ft of PrSM operations, ~400 current U.S. employees, and its >$7 billion cumulative investment in capacity expansion.
Cars.com (NYSE: CARS) announced its 2026 Dealer of the Year Awards on March 18, 2026, naming top dealers across the U.S. and Canada.
The awards used Cars.com's review data — about 16 million total reviews and 1.3 million in 2025 — plus average star rating, review count and dealer response rate to select winners.
White Mountains (NYSE: WTM) declared an $1.00 per share annual dividend at its February 26, 2026 board meeting. The dividend is payable in cash on March 25, 2026 to holders of record at the close of business on March 16, 2026.
The company is a Bermuda‑domiciled financial services holding company traded as WTM (New York) and WTM.BH (Bermuda). Contact: Rob Seelig, (603) 640-2212.
Cars.com (NYSE: CARS) reported Q4 2025 revenue of $183.9M and record full‑year revenue of $723.2M. Dealer customers grew to 19,544. Q4 net income was $7.4M; full‑year net income was $20.1M. Adjusted EBITDA was $54.9M in Q4 and $211.1M for 2025.
Cash from operations was $151.6M, free cash flow $125.7M, total debt $455.0M, and the company repurchased 7.1M shares for $86.0M in 2025.
Adient (NYSE: ADNT) unveiled Sculpted Soft Trim, a formed, soft and breathable seat-trim solution that reduces sewing and enables complex 3D shapes, embossing and mixed-material panels. Cycle times are roughly 50% of traditional forming, and the product is available globally and in production on multiple OEM seats this year.
The technology can replace up to twelve individual patterns and sew lines for some parts, improve craftsmanship on concave surfaces, and support a wide range of fabrics and vinyls.
Cars.com (NYSE: CARS) expects to report fourth-quarter and full-year 2025 financial results on Thursday, February 26, 2026. The company will host a conference call and live webcast at 8:00 a.m. CT / 9:00 a.m. ET the same day to discuss results.
The call will be led by CEO Tobias Hartmann and CFO Sonia Jain. Investors can listen via webcast at investor.cars.com, and a replay will be posted afterwards in the Events section of the investor relations website.